Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Shipment of R21 malaria vaccine to Central African Republic marks latest milestone for child survival

Public engagement

Last month, UNICEF delivered over 43,200 doses of the R21/Matrix-M malaria vaccine developed through collaboration between Oxford University’s Jenner Institute and Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology, by air to Bangui, Central African Republic, with further shipment of about 163,800 doses to follow, which is allocated for children in the CAR currently.

Communication, Narratives and Antimicrobial Resistance

Events Innovation

The World Health Organisation has declared Antimicrobial Resistance (AMR) as one of the ‘top global and public health development threats.’ The Communication, Narratives and Antimicrobial Resistance conference took place on the 16th of May at Merton College, Oxford, as part of the TORCH Medical Humanities programme in an effort to approach the problem from a Humanities perspective. The focus of the day was the power of narrative and communication in discussions around antimicrobial resistance. This blog reviews the discussions of the day. Written by Alberto Giubilini, Sally Frampton, Tess Johnson and Will Matlock

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Innovation Research

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.

Forecasting how best to control and eliminate Neglected Tropical Diseases

Innovation Partnerships Research

Neglected tropical diseases (NTDs) are a major cause of death, disability, and economic hardship worldwide, particularly in low- and middle-income countries. While many of these diseases are targeted for control, elimination, or eradication by 2030, achieving those targets will be challenging due to disruptions to programmes related to the COVID-19 pandemic and differences in disease transmission across regions, which requires tailoring interventions to local settings.

Interview with Diagnostics in Tropical and Infectious Diseases(DiTi) award recipient Dr Christopher Chew

Awards and Appointments General Partnerships Staff and Student stories

Global Health research at the University of Oxford and its partners is broad reaching, bringing significant impact across all academic disciplines of medicine, the physical and life sciences, social sciences and humanities. The Diagnostics in Tropical and Infectious Disease (DiTi) award, run by the Translational Research Office, aims to strengthen the long-term partnership between Oxford University and Mahidol University by establishing partnerships and supporting collaborative projects to develop diagnostic devices for tropical and infectious diseases, with the goal of driving more translational research initiatives in global health. Read this interview from award winner Dr Chris Chew.

Sixty Seconds with Professor Alan Bernstein

General Staff and Student stories

Professor Alan Bernstein is Director of Global Health. The Oxford Global Health initiative brings together researchers from diverse disciplines and showcases the ongoing range of impactful global health research at Oxford. In this Sixty Seconds interview, we hear from Alan about his career to date, his vision for Oxford Global Health, and the lessons he has learnt throughout his career.

Novel inhaled TB vaccine

General Research

The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin

First-in-human vaccine trial for deadly Nipah virus launched

Clinical Trials General Research

First clinical trial participants received doses of the ChAdOx1 NipahB vaccine over the last week at University of Oxford. UK trial is first step to developing a vaccine against Nipah virus – a devastating disease mostly found in South-East Asia – that can be fatal in up to 75% of cases. The milestone clinical trial comes as the global health community marks the 25th anniversary of the first Nipah virus outbreaks. There are still no approved vaccines or treatments for the disease.

Sir Stewart Cole joins the Ineos Oxford Institute for antimicrobial research as Executive Chair

Awards and Appointments General

Sir Stewart Cole, KCMG, FRS has joined the Ineos Oxford Institute for antimicrobial research (IOI) as Executive Chair. The IOI is a world-leading centre of research, training, and education in the field of antimicrobial resistance (AMR) based at the University of Oxford. It was established thanks to an unprecedented £100 million gift from INEOS, one of the world’s largest chemical companies.

Malaria chemoprevention after hospital discharge reduced mortality and sickness in children recovering from severe anaemia

General Research

A systematic review and individual patient meta-analysis found that malaria chemoprevention after hospital discharge reduces deaths in children recovering from severe anaemia by 70%, and hospital readmission by 55%.

Early-life diseases linked to lifelong childlessness

General Research

A ground-breaking study, published in Nature Human Behaviour, reveals a significant association between 74 early-life diseases and the likelihood of remaining childless throughout one's life, with 33 of these diseases prevalent in both women and men.

Report sets out recommendations for reducing inequities and improving care for babies of Asian and Black mothers

General Research

The Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across UK (MBRRACE) collaboration, which is co-led by The Infant Mortality and Morbidity Studies (TIMMS) group at the University of Leicester and the Nuffield Department of Population Health's Perinatal Epidemiology Unit (NPEU), has today published the results of a confidential enquiry into the care of Black and Asian babies born in the UK in 2019.

Oxford scientist to lead international transdisciplinary consortium towards delivering NetZero Healthcare

Awards and Appointments General

The European Union Horizon Europe (with joint funding from UK Research Innovation) has awarded NetZeroAICT Consortium major funding to develop a novel technology with great potentials to promote climate neutral and sustainable health care.

Oxford Vaccine Group, Department of Paediatrics, University of Oxford receives £7.8 million in research funding to fight pandemic and epidemic threats

General Research

Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential. The awards will fund research into vaccines against: Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.

1 in 4 malaria patients in Africa receive suboptimal dose of antimalarial drugs

General Research

A new study estimates that nearly 1 in 4 people with P. falciparum malaria in Africa are at risk of receiving too low a dose of artemisinin combination therapies (ACTs), increasing the chance of treatment failure and the risk that malarial parasites develop resistance to the drug they were exposed to.

Antibiotic resistance genes are spread more widely between bacteria than previously thought

General Research

A new study published in The Lancet Microbe has found that the transfer of antibiotic resistance genes between different bacteria is considerably more widespread than previously thought.

Race to cure type 1 diabetes gets a new boost

General Research

Radcliffe Department of Medicine (RDM) group awarded £2.55 million for diabetes research.

Alan Bernstein at Rethinking Global Engagement 2023

Events General

The University of Oxford Director of Global Health, Professor Alan Bernstein, emphasised the importance of young people and the need for Universities to take on the challenges facing our planet at Rethinking Global Engagement 2023.

The Global Health Network launch The 1000 Challenge

General Research

The Global Health Network and Nursing Now Challenge launch The 1000 Challenge, a global research leadership initiative to enable health professionals to ask locally important questions to generate evidence. The initiative aims to change practice and management to improve patient management, care, or treatment in a commitment to advance Health for All.

Load More